Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance

AbbVie IncTrade
iShares 20 Plus Year Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? AbbVie Inc trades at $249.28 (market cap $441.94B), while iShares 20 Plus Year Treasury Bond ETF trades at $82.34. The key difference: AbbVie Inc pays a 2.77% dividend while iShares 20 Plus Year Treasury Bond ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

ABBVTLT
Market Cap
$441.94B
Sector
Health
52-Week High
$263.58$92.06
52-Week Low
$197.38$82.05
Enterprise Value
$506.19B
Dividend Yield
2.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.

Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.

iShares 20 Plus Year Treasury Bond ETF

TLT, the iShares 20+ Year Treasury Bond ETF, trades at $82.40, up 0.43% on the day, amid a bearish technical signal with selling pressure dominating moving averages. Recent news highlights rising Treasury yields and inflation concerns, with institutional buying noted. The ETF provides exposure to long-term U.S. government bonds, with dividend distributions continuing regularly.

Outlook remains cautious due to interest rate uncertainty and inflation pressures, offering income but facing headwinds from potential Fed policy shifts. Key risks include yield volatility and macroeconomic factors impacting bond prices.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About iShares 20 Plus Year Treasury Bond ETF

The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.

Read more on TLT